Skip to content

Avidity Partners Management LP

Follow

13F filer, CIK 1791827, DALLAS, TX

Avidity Partners Management LP reported $488,204,016 across 18 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 98.09% of the portfolio.

Accepted , ingested 13F-HR 0001791827-26-000008

Period
2026-09-30
Reported value
$488M
Holdings
18
Top 10 weight
98.09%
New
1
Sold out
28

Part of the filer group Avidity Partners Management LP

  • Avidity Capital Partners Fund (GP) LP
  • Avidity Capital Partners (GP) LLC
  • Avidity Partners Management (GP) LLC
  • Avidity Private Master Fund I LP
  • Michael Gregory
How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
JBIOadded+299,292$4.21M
ORKAadded+25,000$2.08M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
DNTHreduced-204,591-$18M
SENSreduced-1,500,000-$15.3M
RGENexited-77,800-$10.6M
PVLAreduced-50,000-$6.9M
TEVAexited-200,000-$6.78M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001791827-26-000008, largest first. % of portfolio is the value over $427,947,516, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,873,000 shares; 2025Q1: 1,720,902 shares; 2025Q2: 1,742,902 shares; 2025Q3: 3,204,184 shares; 2025Q4: 2,104,184 shares; 2026Q1: 2,104,184 shares; 2026Q2: 2,104,184 shares; 2026Q3: 1,899,593 shares 1,899,593$167M39.08%-204,591Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,097,800 shares; 2025Q1: 980,942 shares; 2025Q2: 1,499,942 shares; 2025Q3: 1,600,899 shares; 2025Q4: 1,472,699 shares; 2026Q1: 1,288,948 shares; 2026Q2: 1,398,948 shares; 2026Q3: 1,348,948 shares 1,348,948$95.6M22.35%-50,000Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 352,124 shares; 2025Q1: 352,124 shares; 2025Q2: 352,124 shares; 2025Q3: 660,424 shares; 2025Q4: 660,424 shares; 2026Q1: 760,424 shares; 2026Q2: 760,424 shares; 2026Q3: 785,424 shares 785,424$65.4M15.29%+25,000Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,127,186 shares; 2025Q3: 1,127,186 shares; 2025Q4: 1,400,708 shares; 2026Q1: 1,400,708 shares; 2026Q2: 1,700,708 shares; 2026Q3: 2,000,000 shares 2,000,000$28.1M6.57%+299,292Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 11,300 shares; 2025Q2: 11,300 shares; 2025Q3: 140,300 shares; 2025Q4: 140,300 shares; 2026Q1: 400,000 shares; 2026Q2: 550,000 shares; 2026Q3: 550,000 shares 550,000$25.2M5.89%0Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,694,600 shares; 2025Q1: 2,197,270 shares; 2025Q2: 1,858,596 shares; 2025Q3: 2,994,033 shares; 2025Q4: 3,210,733 shares; 2026Q1: 6,049,999 shares; 2026Q2: 6,299,999 shares; 2026Q3: 6,067,999 shares 6,067,999$16.7M3.9%-232,000Timeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 468,566 shares; 2026Q2: 484,200 shares; 2026Q3: 484,200 shares 484,200$9.43M2.2%0Timeline
IMUXIMMUNIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 669,941 shares; 2026Q3: 669,941 shares 669,941$6.23M1.46%0Timeline
MOBIMOBIA MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 798,282 shares; 2026Q3: 324,676 shares 324,676$3.07M0.72%-473,606Timeline
PVLAPALVELLA THERAPEUTICS INC NEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 19,300 shares; 2026Q1: 70,000 shares; 2026Q2: 70,000 shares; 2026Q3: 20,000 shares 20,000$2.76M0.64%-50,000Timeline
NVCTNUVECTIS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 200,000 shares; 2026Q3: 100,415 shares 100,415$2.12M0.5%-99,585Timeline
MSLESATELLOS BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 387,769 shares; 2026Q2: 387,769 shares; 2026Q3: 164,019 shares 164,019$1.39M0.33%-223,750Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,477,200 shares; 2025Q1: 7,477,200 shares; 2025Q2: 7,477,255 shares; 2025Q3: 8,981,855 shares; 2025Q4: 5,504,855 shares; 2026Q1: 4,998,267 shares; 2026Q2: 4,998,267 shares; 2026Q3: 4,060,254 shares 4,060,254$1.22M0.29%-938,013Timeline
KPTIKARYOPHARM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 134,566 shares; 2025Q2: 134,566 shares; 2025Q3: 134,566 shares; 2025Q4: 134,566 shares; 2026Q1: 463,741 shares; 2026Q2: 924,487 shares; 2026Q3: 884,900 shares 884,900$1.08M0.25%-39,587Timeline
SENSSENSEONICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,600,000 shares; 2026Q3: 100,000 shares 100,000$1.02M0.24%-1,500,000Timeline
SCYXSCYNEXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 260,206 shares; 2026Q3: 153,613 shares 153,613$759K0.18%-106,593Timeline
AVLNAVALYN PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 60,000 shares; 2026Q3: 20,000 shares 20,000$570K0.13%-40,000Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
CGONCG ONCOLOGY INC COMMON STOCKcall850,000$60.3Mnew

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RGENREPLIGEN CORP77,800$10.6Mshares
TEVATEVA PHARMACEUTICAL INDS LTD200,000$6.78Mshares
DXCMDEXCOM INC100,000$6.74Mshares
TEMTEMPUS AI INC105,000$6.08Mshares
MDTMEDTRONIC PLC70,000$5.48Mshares
VIRVIR BIOTECHNOLOGY INC519,300$5.29Mshares
GPCRSTRUCTURE THERAPEUTICS INC98,000$5.26Mshares
EHCENCOMPASS HEALTH CORP42,000$4.25Mshares
TENXTENAX THERAPEUTICS INC265,934$3.87Mshares
PODDINSULET CORP24,000$3.65Mshares
BSXBOSTON SCIENTIFIC CORP80,000$3.41Mshares
ALMRALAMAR BIOSCIENCES INC110,000$2.98Mshares
GILDGILEAD SCIENCES INC20,000$2.53Mshares
CRLCHARLES RIV LABS INTL INC10,000$2.27Mshares
PHATPHATHOM PHARMACEUTICALS INC200,000$2.17Mshares
KLRAKAILERA THERAPEUTICS INC80,000$1.76Mshares
GMABGENMAB A/S50,000$1.37Mshares
NTLAINTELLIA THERAPEUTICS INC75,000$1.27Mshares
CRVSCORVUS PHARMACEUTICALS INC80,000$1.2Mshares
ODDODDITY TECH LTD70,000$1.06Mshares
EVMNEVOMMUNE INC75,000$997Kshares
ABTABBOTT LABORATORIES10,000$907Kshares
BBIOBRIDGEBIO PHARMA INC10,000$745Kshares
PTONPELOTON INTERACTIVE INC100,000$591Kshares
LEGNLEGEND BIOTECH CORP15,000$433Kshares
BBOTBRIDGEBIO ONCOLOGY THERAPEUT43,853$334Kshares
SVRASAVARA INC50,000$308Kshares
TRVITREVI THERAPEUTICS INC6,660$124Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001791827-26-000008 base2026-11-16